Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (3656)	11/4/2000 12:33:03 PM
From: RJMC	Read Replies (3) \| Respond to of 5665

Not too much new in the MTSL Stock Letter. Basically talked about the secondary offering and how well the stock has held up. They still have Immunogen as a buy under $20. Regardless of the reasoning, it seems like the folks at MTSL might be short-changing their customers by effectively saying don't buy this stock unless it dips back under $20. There are no indications whatsoever that this stock will dip back under $20. If it does, it means that it will go way below $20 and MTSL may as well go ahead and say this stock is a buy under $2. If it doesn't, it means good news out of the clinic and the stock will likely go higher than it is right now. In either case, the MTSL people are short-changing their customers. It does no good to wait until the news is already out and say the new buy rating is $50 and the target is $100. This negatively impacts the people who could be buying the stock right now. They really need to re-think what they are saying and how they are saying it. Bob M.